Clinical data concerning DPP4’s role in comorbidities associated with severe COVID-19, particularly in type 2 diabetes (T2D) and cardiometabolic diseases, support its potential involvement in SARS-CoV-2 infection and the pathogenesis of COVID-19 and LC [145]. This evidence concerns the gene DPP4 and laryngotracheoesophageal cleft.